A. Setser

发表

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

C. N. Coleman, V. Rusch, C. Coleman, 2003, Seminars in radiation oncology.

The Cancer Informatics Infrastructure: a new initiative of the National Cancer Institute.

S M Hubbard, A. Setser, S. Hubbard, 2001, Seminars in oncology nursing.

Phase I clinical trial of continuous infusion cyclopentenyl cytosine

A. Chen, J. Grem, C. Allegra, 2004, Cancer Chemotherapy and Pharmacology.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

L. Minasian, E. Basch, A. Bennett, 2017, International journal of radiation oncology, biology, physics.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Lynne Wagner, Dennis P. West, Ethan Basch, 2010, Supportive Care in Cancer.

Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0

A. Setser, Alice Chen, A. Acharya, 2013 .

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.

S. Steinberg, A. Chen, S. Arbuck, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenocarcinoma-( Phosphonacetyl )-l-aspartate in Metastatic Gastrointestinal N Calcium Leucovorin in Combination with A Phase I Study of Continuous Infusion 5-Fluorouracil plus Updated

S. Steinberg, J. Grem, C. Allegra, 2006 .

#420 Common toxicity criteria (ctc) version 2.0: highlights and tools

S. Arbuck, A. Setser, S. Ivy, 1999 .

Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin

I. Pastan, R. Wittes, M. Willingham, 1996, Nature Medicine.

The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials

A. Colevas, A. Setser, A. D. Colevas, 2004 .

Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

M. Lacouture, M. Anadkat, E. Olsen, 2012, Journal of the American Academy of Dermatology.

Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Ethan Basch, E. Basch, A. Colevas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An innovative, web-based reporting system for serious adverse events developed by the cancer therapy evaluation program (CTEP), National Cancer Institute (NCI)

A. Setser, Elizabeth Ness, 2011 .

The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials.

A. Colevas, A. Setser, Ctcae v, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

L. Minasian, E. Basch, A. Bennett, 2017, International journal of radiation oncology, biology, physics.